Armonica Technologies is looking to develop a nanochannel-based sequencing device that uses optical detection.
The startup aims to tap into the $60 billion probiotics industry by sequencing the microbiomes of athletes to identify bacteria that improve performance.
Researchers from the Netherlands Cancer Institute plan to spin out a company to use sequencing-based cellular network mapping to aid in drug development.
Inflammatix hopes to market an 18-gene panel that will be able to tell from a blood sample whether a hospitalized patient has a bacterial, viral, or no infection.
The firm is in the process of commercializing an open, optimizable, high-throughput library preparation instrument for single-cell transcriptome profiling.
The Harvard spinout is commercializing inDrop single-cell sequencing technology developed by Allon Klein.
The firm is considering separating the point-of-care and lab test arms of its business, delisting its shares, and buying back stock from shareholders.
The UCSC spinout plans to launch a handheld nanopore sensor this year and will partner with diagnostic and other companies to develop assays.
The Bridget Ogilvie Building will house sequencing facilities, and the Biodata Innovation Centre will host genomic startups.
ReadCoor is currently using its its technology to map neural circuits in the brain and has projects in the pipeline related to oncology and infectious disease.
The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.
Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.
In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.
China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.